Dexamethasone and COVID-19 Inpatient Mortality : Effect of Dexamethasone on Inpatient Mortality Among Hospitalized COVID-19 Patients

This is a non-randomized, non-interventional study that is part of a research collaboration agreement between the US Food and Drug Administration (FDA) and Aetion to use real-world data to advance the understanding and the natural history of COVID-19 in specific patient populations, as well as treatment and diagnostic patterns during the coronavirus disease (COVID-19) pandemic.This study compares inpatient mortality within 28 days among US patients hospitalized with COVID-19 diagnosis or SARS-CoV-2 infection who initiate dexamethasone treatment with a matched cohort of patients with 'standard of care' who are non-users of corticosteroids of interest (dexamethasone, prednisone, methylprednisolone, hydrocortisone). Patients are compared overall and and stratified by COVID-19 severity subgroups..

Medienart:

Klinische Studie

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

ClinicalTrials.gov - (2023) vom: 18. Apr. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Coronavirus Infections
Recruitment Status: Completed
Study Type: Observational

Anmerkungen:

Source: Link to the current ClinicalTrials.gov record., First posted: June 15, 2021, Last downloaded: ClinicalTrials.gov processed this data on April 26, 2023, Last updated: April 26, 2023

Study ID:

NCT04926571
RQ004-1-20210610

Veröffentlichungen zur Studie:

fisyears:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG007708408